Supernus Pharmaceuticals reported $40.17M in Debt for its fiscal quarter ending in June of 2026.





Debt Change Date
Abbott USD 34.05B 20.19B Mar/2026
ANI Pharmaceuticals USD 607.23M 3.26M Sep/2026
Aurora Cannabis CAD 22.68M 1.18M Jun/2026
Bristol-Myers Squibb USD 42.88B 2.18B Sep/2026
Canopy Growth CAD 277.33M 1.38M Jun/2026
Cara Therapeutics USD 0 0 Mar/2025
Corcept Therapeutics USD 8.99M 430K Sep/2026
Eisai JPY 254.94B 68.86B Sep/2026
Eli Lilly USD 54.91B 11.54B Jun/2026
Novo Nordisk DKK 118.72B 61.75B Mar/2025
Pacira USD 293.59M 69.53M Sep/2026
Perrigo USD 3.29B 337.7M Jun/2026
Pfizer USD 62.67B 523M Sep/2026
Supernus Pharmaceuticals USD 40.17M 733K Jun/2026
United Therapeutics USD 200M 100M Mar/2025
Xeris Pharmaceuticals USD 289.44M 30.89M Jun/2026